Famewave Ltd.

Biond Biologics Ltd.

Ccam Biotherapeutics Ltd.

Biond Biologies Ltd.

Ramot at Tel-aviv University Ltd.

Tel Hashomer Medical Research Infrastructure and Services Ltd.

Yair Sapir

Ilana Mandel

Gal Markel

Tehila Ben-Moshe

Jacob Schachter

Rona Ortenberg

Avidor Shulman

Motti Hakim

Dror Alishekevitz

Dana Haves Ziv

Timothy David Jones

Robert George E Holgate

Tsuri Peretz

Tehila Ben-moshe

Anna Fridman-Dror

Ilana Goldshtein

Francis Joseph Carr

Edna Meilin

Tehila Ben Moshe

Francis J Carr

Ayala Lewkowicz

Lilach Chen Zeltsburg

Ilana Mande

Yossi Gottfried

Rotem Faygenboim-Ornai

Orit Shilovitzky

Rozi Ravit Uzan Gueta

Robert George Holgate

Rotem Faygenboim-ornai

The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.

Methods of use for anti-ILT2 antibodies

Methods of treating cancer and improving immunotherapies comprising decreasing soluble immune receptor levels are provided. Agents that bind membranal immune receptor and inhibit proteolytic cleavage of the receptor and agents that bind soluble immune receptor and that are neither receptor agonists nor antagonists are also provided, as are methods of producing these agents.

Methods and compositions for decreasing soluble immune receptor CD28

The present disclosure provides monoclonal anti-ILT2 antibodies or antigen-binding fragments thereof, as well as pharmaceutical compositions comprising the same and methods of producing the same. Also provided are methods of treating cancer using the antibodies or compositions of the present disclosure. Methods of patient selection are also provided.

Antibodies against ILT2 and use thereof

The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)

Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.

Humanized antibodies against CEACAM1

Polynucleotides encoding humanized antibodies against CEACAM1

Antibodies against ILT2

The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.

Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy

The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

Growing community of inventors

Manof, Israel

Yair Sapir